Meningitis Vaccine (Ages 10-17)

Study of an investigational pentavalent meningococcal ABCYW vaccine against meningococcal disease in adults and adolescents

The rise in infectious disease outbreaks in recent decades

underscores the need to find better and safer vaccines to protect individuals and the public.

To answer the need for a vaccine providing protection against

the 5 most epidemiologically relevant N. meningitidis serogroups worldwide (A, B, C, W, and Y) and to reduce the need for multiple injections with multiple vaccines, Sanofi is developing a new pentavalent meningococcal ABCYW vaccine, referred to hereafter as MenPenta.

The purpose of this Phase I/II study is to assess the safety and

immunogenicity of 2 formulations of MenPenta relative to the

safety and immunogenicity of the licensed comparator vaccines.